降尿酸治疗对心血管和肾脏结局影响的系统评价与Meta分析
该系统评价纳入28项随机对照试验共6458例参与者,评估降尿酸治疗至少6个月对心血管和肾脏结局的影响。结果显示降尿酸治疗未显著降低主要不良心血管事件、全因死亡或肾衰竭风险,但减缓了GFR下降斜率并降低了血压。
要点
- 降尿酸治疗未显著降低主要不良心血管事件风险(RR 0.93,95%CI 0.74-1.18)。
- 降尿酸治疗未显著降低全因死亡(RR 1.04,95%CI 0.78-1.39)或肾衰竭风险(RR 0.97,95%CI 0.61-1.54)。
- 降尿酸治疗减缓GFR下降(WMD 1.18 ml/min/1.73m2/年,95%CI 0.44-1.91)并降低血压。
核心结论
- 降尿酸治疗未在主要不良心血管事件、全因死亡和肾衰竭等临床结局上显示获益。
- 证据不足以支持通过降尿酸治疗改善肾脏和心血管结局。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane数据库至2020年7月。
- 纳入28项前瞻性随机对照试验,共6458例参与者,干预至少6个月。
- 主要结局包括主要不良心血管事件、全因死亡、肾衰竭事件、血压和GFR。
主要发现
- 主要不良心血管事件506例,降尿酸治疗组与对照组风险比0.93(95%CI 0.74-1.18)。
- 全因死亡风险比1.04(95%CI 0.78-1.39),肾衰竭事件266例,风险比0.97(95%CI 0.61-1.54)。
- GFR下降斜率加权均数差1.18 ml/min per 1.73 m2 per year(95%CI 0.44-1.91)。
- 收缩压加权均数差-3.45 mm Hg(95%CI -6.10至-0.80),舒张压-2.02 mm Hg(95%CI -3.25至-0.78)。
- 不良事件风险比1.01(95%CI 0.94-1.08),两组无显著差异。
临床怎么用
- 不应仅以降尿酸治疗作为改善心血管或肾脏临床结局的主要策略。
- 对于高尿酸血症患者,降尿酸治疗可能有助于减缓GFR下降和降低血压,但需权衡临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Several clinical practice guidelines noted the potential benefits of urate-lowering therapy on cardiovascular disease and CKD progression; however, the effect of this regimen remains uncertain. In this systematic review, we aimed to evaluate the efficacy of urate-lowering therapy on major adverse cardiovascular events, all-cause mortality, kidney failure events, BP, and GFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We systematically searched MEDLINE, Embase, and the Cochrane databases for trials published through July 2020. We included prospective, randomized, controlled trials assessing the effects of urate-lowering therapy for at least 6 months on cardiovascular or kidney outcomes. Relevant information was extracted into a spreadsheet by two authors independently. Treatment effects were summarized using random effects meta-analysis. RESULTS: We identified 28 trials including a total of 6458 participants with 506 major adverse cardiovascular events and 266 kidney failure events. Overall urate-lowering therapy did not show benefits on major adverse cardiovascular events (risk ratio, 0.93; 95% confidence interval, 0.74 to 1.18) and all-cause mortality (risk ratio, 1.04; 95% confidence interval, 0.78 to 1.39) or kidney failure (risk ratio, 0.97; 95% confidence interval, 0.61 to 1.54). Nevertheless, urate-lowering therapy attenuated the decline in the slope of GFR (weighted mean difference, 1.18 ml/min per 1.73 m2 per year; 95% confidence interval, 0.44 to 1.91) and lowered the mean BP (systolic BP: weighted mean difference, -3.45 mm Hg; 95% confidence interval, -6.10 to -0.80; diastolic BP: weighted mean difference, -2.02 mm Hg; 95% confidence interval, -3.25 to -0.78). There was no significant difference (risk ratio, 1.01; 95% confidence interval, 0.94 to 1.08) in the risk of adverse events between the participants receiving urate-lowering therapy and the control group. CONCLUSIONS: Urate-lowering therapy did not produce benefits on the clinical outcomes, including major adverse cardiovascular events, all-cause mortality, and kidney failure. Thus, there is insufficient evidence to support urate lowering in patients to improve kidney and cardiovascular outcomes.
引用
- Chen Q, Wang Z, Zhou J, et al. Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2020. PMID: 33055192. doi:10.2215/CJN.05190420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。